Rafferty Asset Management LLC acquired a new position in Acelyrin, Inc. (NASDAQ:SLRN – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 173,696 shares of the company’s stock, valued at approximately $1,766,000.
Several other institutional investors have also added to or reduced their stakes in SLRN. Osaic Holdings Inc. bought a new stake in Acelyrin in the second quarter worth about $25,000. Amalgamated Bank bought a new stake in Acelyrin in the third quarter worth about $44,000. Tower Research Capital LLC TRC bought a new stake in Acelyrin in the second quarter worth about $64,000. Strs Ohio bought a new stake in Acelyrin in the third quarter worth about $71,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Acelyrin during the third quarter valued at approximately $73,000. Institutional investors own 94.68% of the company’s stock.
Wall Street Analysts Forecast Growth
SLRN has been the subject of several research analyst reports. Wells Fargo & Company initiated coverage on shares of Acelyrin in a research note on Wednesday, December 13th. They set an “equal weight” rating and a $11.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Acelyrin in a research note on Tuesday, November 28th. Morgan Stanley decreased their price target on shares of Acelyrin from $19.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 29th. Citigroup assumed coverage on shares of Acelyrin in a research note on Friday, December 8th. They set a “neutral” rating and a $8.00 price target for the company. Finally, Jefferies Financial Group reduced their price objective on shares of Acelyrin from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Tuesday, November 28th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.67.
Check Out Our Latest Analysis on Acelyrin
Acelyrin Stock Down 1.6 %
NASDAQ SLRN opened at $7.52 on Friday. The firm’s fifty day simple moving average is $7.44 and its two-hundred day simple moving average is $11.61. Acelyrin, Inc. has a 12-month low of $5.70 and a 12-month high of $29.88.
Insiders Place Their Bets
In other Acelyrin news, CEO Shao-Lee Lin sold 15,701 shares of Acelyrin stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $7.60, for a total value of $119,327.60. Following the transaction, the chief executive officer now directly owns 1,587,335 shares of the company’s stock, valued at $12,063,746. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Acelyrin Profile
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
See Also
Want to see what other hedge funds are holding SLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acelyrin, Inc. (NASDAQ:SLRN – Free Report).
Receive News & Ratings for Acelyrin Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Acelyrin and related companies with MarketBeat.com’s FREE daily email newsletter.